Loading…
Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death
Metabolic reprogramming is emerging as a cancer vulnerability that could be therapeutically exploitable using different approaches, including amino acid depletion for those tumors that rely on exogenous amino acids for their maintenance. ʟ-Asparaginase (ASNase) has contributed to a significant impro...
Saved in:
Published in: | Blood advances 2020-09, Vol.4 (18), p.4312-4326 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3949-61f80997409e2c1a4a8c109d40f037ad5a493d580d3a92f19b872375f3f7bc183 |
---|---|
cites | cdi_FETCH-LOGICAL-c3949-61f80997409e2c1a4a8c109d40f037ad5a493d580d3a92f19b872375f3f7bc183 |
container_end_page | 4326 |
container_issue | 18 |
container_start_page | 4312 |
container_title | Blood advances |
container_volume | 4 |
creator | Soncini, Debora Minetto, Paola Martinuzzi, Claudia Becherini, Pamela Fenu, Valeria Guolo, Fabio Todoerti, Katia Calice, Giovanni Contini, Paola Miglino, Maurizio Rivoli, Giulia Aquino, Sara Dominietto, Alida Cagnetta, Antonia Passalacqua, Mario Bruzzone, Santina Nencioni, Alessio Zucchetti, Massimo Ceruti, Tommaso Neri, Antonino Lemoli, Roberto M. Cea, Michele |
description | Metabolic reprogramming is emerging as a cancer vulnerability that could be therapeutically exploitable using different approaches, including amino acid depletion for those tumors that rely on exogenous amino acids for their maintenance. ʟ-Asparaginase (ASNase) has contributed to a significant improvement in acute lymphoblastic leukemia outcomes; however, toxicity and resistance limit its clinical use in other tumors. Here, we report that, in multiple myeloma (MM) cells, the DNA methylation status is significantly associated with reduced expression of ASNase-related gene signatures, thus suggesting ASNase sensitivity for this tumor. Therefore, we tested the effects of ASNase purified from Erwinia chrysanthemi (Erw-ASNase), combined with the next-generation proteasome inhibitor (PI) carfilzomib. We observed an impressive synergistic effect on MM cells, whereas normal peripheral blood mononuclear cells were not affected. Importantly, this effect was associated with increased reactive oxygen species (ROS) generation, compounded mitochondrial damage, and Nrf2 upregulation, regardless of the c-Myc oncogenic-specific program. Furthermore, the cotreatment resulted in genomic instability and DNA repair mechanism impairment via increased mitochondrial oxidative stress, which further enhanced its antitumor activity. Interestingly, carfilzomib-resistant cells were found to be highly dependent on amino acid starvation, as reflected by their higher sensitivity to Erw-ASNase treatment compared with isogenic cells. Overall, by affecting several cellular programs, Erw-ASNase makes MM cells more vulnerable to carfilzomib, providing proof of concept for clinical use of this combination as a novel strategy to enhance PI sensitivity in MM patients.
•Metabolic landscape of MM cells supports the relevance of amino acid depletion as a novel anti-MM therapeutic strategy.•Erw-ASNase combined with proteasome inhibition results in synergistic anti-MM effects by inducing ROS-mediated cell death.
[Display omitted] |
doi_str_mv | 10.1182/bloodadvances.2020001639 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7509874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2473952920315123</els_id><sourcerecordid>2442213993</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3949-61f80997409e2c1a4a8c109d40f037ad5a493d580d3a92f19b872375f3f7bc183</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhSMEolXpKyAv2aT4JxnHG6RSUajUqhI_a-vGvslclNiDnRmp3fMcvA9P1URTBrpiZUv-zjn3-hQFE_xMiEa-bYcYPfgdBIf5THLJORcrZZ4Vx7LSqjS10s8Pd2mOitOcvy-QXqnayJfFkZJG1Eab4-Ln-UghMnDkmcfNgBPFwKZEfY8JPWvv2O9fJeQNJOgpQEaWMWSa6B4zu7lhDochsykyB6mj4T6O1C4qCn7rKPRspCm6dQw-EbDPt1_KET3BNHsv0jkUpvWr4kUHQ8bTx_Ok-Hb54evFp_L69uPVxfl16ZSpTLkSXcON0RU3KJ2AChonuPEV77jS4GuojPJ1w70CIzth2kZLpetOdbp1olEnxbu972bbzmM4DFOCwW4SjZDubASyT18CrW0fd1bX3DS6mg3ePBqk-GOLebIj5WUPCBi32cqqklIoY9SMNnvUpZhzwu4QI7hdirRPirR_i5ylr_8d8yD8U9sMvN8DOH_WjjDZ7AhnG08J3WR9pP-nPACQFLfb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2442213993</pqid></control><display><type>article</type><title>Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death</title><source>PubMed (Medline)</source><source>ScienceDirect (Online service)</source><creator>Soncini, Debora ; Minetto, Paola ; Martinuzzi, Claudia ; Becherini, Pamela ; Fenu, Valeria ; Guolo, Fabio ; Todoerti, Katia ; Calice, Giovanni ; Contini, Paola ; Miglino, Maurizio ; Rivoli, Giulia ; Aquino, Sara ; Dominietto, Alida ; Cagnetta, Antonia ; Passalacqua, Mario ; Bruzzone, Santina ; Nencioni, Alessio ; Zucchetti, Massimo ; Ceruti, Tommaso ; Neri, Antonino ; Lemoli, Roberto M. ; Cea, Michele</creator><creatorcontrib>Soncini, Debora ; Minetto, Paola ; Martinuzzi, Claudia ; Becherini, Pamela ; Fenu, Valeria ; Guolo, Fabio ; Todoerti, Katia ; Calice, Giovanni ; Contini, Paola ; Miglino, Maurizio ; Rivoli, Giulia ; Aquino, Sara ; Dominietto, Alida ; Cagnetta, Antonia ; Passalacqua, Mario ; Bruzzone, Santina ; Nencioni, Alessio ; Zucchetti, Massimo ; Ceruti, Tommaso ; Neri, Antonino ; Lemoli, Roberto M. ; Cea, Michele</creatorcontrib><description>Metabolic reprogramming is emerging as a cancer vulnerability that could be therapeutically exploitable using different approaches, including amino acid depletion for those tumors that rely on exogenous amino acids for their maintenance. ʟ-Asparaginase (ASNase) has contributed to a significant improvement in acute lymphoblastic leukemia outcomes; however, toxicity and resistance limit its clinical use in other tumors. Here, we report that, in multiple myeloma (MM) cells, the DNA methylation status is significantly associated with reduced expression of ASNase-related gene signatures, thus suggesting ASNase sensitivity for this tumor. Therefore, we tested the effects of ASNase purified from Erwinia chrysanthemi (Erw-ASNase), combined with the next-generation proteasome inhibitor (PI) carfilzomib. We observed an impressive synergistic effect on MM cells, whereas normal peripheral blood mononuclear cells were not affected. Importantly, this effect was associated with increased reactive oxygen species (ROS) generation, compounded mitochondrial damage, and Nrf2 upregulation, regardless of the c-Myc oncogenic-specific program. Furthermore, the cotreatment resulted in genomic instability and DNA repair mechanism impairment via increased mitochondrial oxidative stress, which further enhanced its antitumor activity. Interestingly, carfilzomib-resistant cells were found to be highly dependent on amino acid starvation, as reflected by their higher sensitivity to Erw-ASNase treatment compared with isogenic cells. Overall, by affecting several cellular programs, Erw-ASNase makes MM cells more vulnerable to carfilzomib, providing proof of concept for clinical use of this combination as a novel strategy to enhance PI sensitivity in MM patients.
•Metabolic landscape of MM cells supports the relevance of amino acid depletion as a novel anti-MM therapeutic strategy.•Erw-ASNase combined with proteasome inhibition results in synergistic anti-MM effects by inducing ROS-mediated cell death.
[Display omitted]</description><identifier>ISSN: 2473-9529</identifier><identifier>EISSN: 2473-9537</identifier><identifier>DOI: 10.1182/bloodadvances.2020001639</identifier><identifier>PMID: 32915979</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Amino Acids ; Asparaginase - pharmacology ; Cell Death ; Humans ; Leukocytes, Mononuclear ; Lymphoid Neoplasia ; Mitochondria ; Oligopeptides ; Reactive Oxygen Species</subject><ispartof>Blood advances, 2020-09, Vol.4 (18), p.4312-4326</ispartof><rights>2020 American Society of Hematology</rights><rights>2020 by The American Society of Hematology.</rights><rights>2020 by The American Society of Hematology 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3949-61f80997409e2c1a4a8c109d40f037ad5a493d580d3a92f19b872375f3f7bc183</citedby><cites>FETCH-LOGICAL-c3949-61f80997409e2c1a4a8c109d40f037ad5a493d580d3a92f19b872375f3f7bc183</cites><orcidid>0000-0001-6094-4351 ; 0000-0001-9143-3714 ; 0000-0003-3166-6078 ; 0000-0001-7388-188X ; 0000-0002-2545-1401 ; 0000-0002-1530-6729</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509874/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2473952920315123$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32915979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soncini, Debora</creatorcontrib><creatorcontrib>Minetto, Paola</creatorcontrib><creatorcontrib>Martinuzzi, Claudia</creatorcontrib><creatorcontrib>Becherini, Pamela</creatorcontrib><creatorcontrib>Fenu, Valeria</creatorcontrib><creatorcontrib>Guolo, Fabio</creatorcontrib><creatorcontrib>Todoerti, Katia</creatorcontrib><creatorcontrib>Calice, Giovanni</creatorcontrib><creatorcontrib>Contini, Paola</creatorcontrib><creatorcontrib>Miglino, Maurizio</creatorcontrib><creatorcontrib>Rivoli, Giulia</creatorcontrib><creatorcontrib>Aquino, Sara</creatorcontrib><creatorcontrib>Dominietto, Alida</creatorcontrib><creatorcontrib>Cagnetta, Antonia</creatorcontrib><creatorcontrib>Passalacqua, Mario</creatorcontrib><creatorcontrib>Bruzzone, Santina</creatorcontrib><creatorcontrib>Nencioni, Alessio</creatorcontrib><creatorcontrib>Zucchetti, Massimo</creatorcontrib><creatorcontrib>Ceruti, Tommaso</creatorcontrib><creatorcontrib>Neri, Antonino</creatorcontrib><creatorcontrib>Lemoli, Roberto M.</creatorcontrib><creatorcontrib>Cea, Michele</creatorcontrib><title>Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death</title><title>Blood advances</title><addtitle>Blood Adv</addtitle><description>Metabolic reprogramming is emerging as a cancer vulnerability that could be therapeutically exploitable using different approaches, including amino acid depletion for those tumors that rely on exogenous amino acids for their maintenance. ʟ-Asparaginase (ASNase) has contributed to a significant improvement in acute lymphoblastic leukemia outcomes; however, toxicity and resistance limit its clinical use in other tumors. Here, we report that, in multiple myeloma (MM) cells, the DNA methylation status is significantly associated with reduced expression of ASNase-related gene signatures, thus suggesting ASNase sensitivity for this tumor. Therefore, we tested the effects of ASNase purified from Erwinia chrysanthemi (Erw-ASNase), combined with the next-generation proteasome inhibitor (PI) carfilzomib. We observed an impressive synergistic effect on MM cells, whereas normal peripheral blood mononuclear cells were not affected. Importantly, this effect was associated with increased reactive oxygen species (ROS) generation, compounded mitochondrial damage, and Nrf2 upregulation, regardless of the c-Myc oncogenic-specific program. Furthermore, the cotreatment resulted in genomic instability and DNA repair mechanism impairment via increased mitochondrial oxidative stress, which further enhanced its antitumor activity. Interestingly, carfilzomib-resistant cells were found to be highly dependent on amino acid starvation, as reflected by their higher sensitivity to Erw-ASNase treatment compared with isogenic cells. Overall, by affecting several cellular programs, Erw-ASNase makes MM cells more vulnerable to carfilzomib, providing proof of concept for clinical use of this combination as a novel strategy to enhance PI sensitivity in MM patients.
•Metabolic landscape of MM cells supports the relevance of amino acid depletion as a novel anti-MM therapeutic strategy.•Erw-ASNase combined with proteasome inhibition results in synergistic anti-MM effects by inducing ROS-mediated cell death.
[Display omitted]</description><subject>Amino Acids</subject><subject>Asparaginase - pharmacology</subject><subject>Cell Death</subject><subject>Humans</subject><subject>Leukocytes, Mononuclear</subject><subject>Lymphoid Neoplasia</subject><subject>Mitochondria</subject><subject>Oligopeptides</subject><subject>Reactive Oxygen Species</subject><issn>2473-9529</issn><issn>2473-9537</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkc1u1DAUhSMEolXpKyAv2aT4JxnHG6RSUajUqhI_a-vGvslclNiDnRmp3fMcvA9P1URTBrpiZUv-zjn3-hQFE_xMiEa-bYcYPfgdBIf5THLJORcrZZ4Vx7LSqjS10s8Pd2mOitOcvy-QXqnayJfFkZJG1Eab4-Ln-UghMnDkmcfNgBPFwKZEfY8JPWvv2O9fJeQNJOgpQEaWMWSa6B4zu7lhDochsykyB6mj4T6O1C4qCn7rKPRspCm6dQw-EbDPt1_KET3BNHsv0jkUpvWr4kUHQ8bTx_Ok-Hb54evFp_L69uPVxfl16ZSpTLkSXcON0RU3KJ2AChonuPEV77jS4GuojPJ1w70CIzth2kZLpetOdbp1olEnxbu972bbzmM4DFOCwW4SjZDubASyT18CrW0fd1bX3DS6mg3ePBqk-GOLebIj5WUPCBi32cqqklIoY9SMNnvUpZhzwu4QI7hdirRPirR_i5ylr_8d8yD8U9sMvN8DOH_WjjDZ7AhnG08J3WR9pP-nPACQFLfb</recordid><startdate>20200922</startdate><enddate>20200922</enddate><creator>Soncini, Debora</creator><creator>Minetto, Paola</creator><creator>Martinuzzi, Claudia</creator><creator>Becherini, Pamela</creator><creator>Fenu, Valeria</creator><creator>Guolo, Fabio</creator><creator>Todoerti, Katia</creator><creator>Calice, Giovanni</creator><creator>Contini, Paola</creator><creator>Miglino, Maurizio</creator><creator>Rivoli, Giulia</creator><creator>Aquino, Sara</creator><creator>Dominietto, Alida</creator><creator>Cagnetta, Antonia</creator><creator>Passalacqua, Mario</creator><creator>Bruzzone, Santina</creator><creator>Nencioni, Alessio</creator><creator>Zucchetti, Massimo</creator><creator>Ceruti, Tommaso</creator><creator>Neri, Antonino</creator><creator>Lemoli, Roberto M.</creator><creator>Cea, Michele</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6094-4351</orcidid><orcidid>https://orcid.org/0000-0001-9143-3714</orcidid><orcidid>https://orcid.org/0000-0003-3166-6078</orcidid><orcidid>https://orcid.org/0000-0001-7388-188X</orcidid><orcidid>https://orcid.org/0000-0002-2545-1401</orcidid><orcidid>https://orcid.org/0000-0002-1530-6729</orcidid></search><sort><creationdate>20200922</creationdate><title>Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death</title><author>Soncini, Debora ; Minetto, Paola ; Martinuzzi, Claudia ; Becherini, Pamela ; Fenu, Valeria ; Guolo, Fabio ; Todoerti, Katia ; Calice, Giovanni ; Contini, Paola ; Miglino, Maurizio ; Rivoli, Giulia ; Aquino, Sara ; Dominietto, Alida ; Cagnetta, Antonia ; Passalacqua, Mario ; Bruzzone, Santina ; Nencioni, Alessio ; Zucchetti, Massimo ; Ceruti, Tommaso ; Neri, Antonino ; Lemoli, Roberto M. ; Cea, Michele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3949-61f80997409e2c1a4a8c109d40f037ad5a493d580d3a92f19b872375f3f7bc183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Amino Acids</topic><topic>Asparaginase - pharmacology</topic><topic>Cell Death</topic><topic>Humans</topic><topic>Leukocytes, Mononuclear</topic><topic>Lymphoid Neoplasia</topic><topic>Mitochondria</topic><topic>Oligopeptides</topic><topic>Reactive Oxygen Species</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soncini, Debora</creatorcontrib><creatorcontrib>Minetto, Paola</creatorcontrib><creatorcontrib>Martinuzzi, Claudia</creatorcontrib><creatorcontrib>Becherini, Pamela</creatorcontrib><creatorcontrib>Fenu, Valeria</creatorcontrib><creatorcontrib>Guolo, Fabio</creatorcontrib><creatorcontrib>Todoerti, Katia</creatorcontrib><creatorcontrib>Calice, Giovanni</creatorcontrib><creatorcontrib>Contini, Paola</creatorcontrib><creatorcontrib>Miglino, Maurizio</creatorcontrib><creatorcontrib>Rivoli, Giulia</creatorcontrib><creatorcontrib>Aquino, Sara</creatorcontrib><creatorcontrib>Dominietto, Alida</creatorcontrib><creatorcontrib>Cagnetta, Antonia</creatorcontrib><creatorcontrib>Passalacqua, Mario</creatorcontrib><creatorcontrib>Bruzzone, Santina</creatorcontrib><creatorcontrib>Nencioni, Alessio</creatorcontrib><creatorcontrib>Zucchetti, Massimo</creatorcontrib><creatorcontrib>Ceruti, Tommaso</creatorcontrib><creatorcontrib>Neri, Antonino</creatorcontrib><creatorcontrib>Lemoli, Roberto M.</creatorcontrib><creatorcontrib>Cea, Michele</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soncini, Debora</au><au>Minetto, Paola</au><au>Martinuzzi, Claudia</au><au>Becherini, Pamela</au><au>Fenu, Valeria</au><au>Guolo, Fabio</au><au>Todoerti, Katia</au><au>Calice, Giovanni</au><au>Contini, Paola</au><au>Miglino, Maurizio</au><au>Rivoli, Giulia</au><au>Aquino, Sara</au><au>Dominietto, Alida</au><au>Cagnetta, Antonia</au><au>Passalacqua, Mario</au><au>Bruzzone, Santina</au><au>Nencioni, Alessio</au><au>Zucchetti, Massimo</au><au>Ceruti, Tommaso</au><au>Neri, Antonino</au><au>Lemoli, Roberto M.</au><au>Cea, Michele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death</atitle><jtitle>Blood advances</jtitle><addtitle>Blood Adv</addtitle><date>2020-09-22</date><risdate>2020</risdate><volume>4</volume><issue>18</issue><spage>4312</spage><epage>4326</epage><pages>4312-4326</pages><issn>2473-9529</issn><eissn>2473-9537</eissn><abstract>Metabolic reprogramming is emerging as a cancer vulnerability that could be therapeutically exploitable using different approaches, including amino acid depletion for those tumors that rely on exogenous amino acids for their maintenance. ʟ-Asparaginase (ASNase) has contributed to a significant improvement in acute lymphoblastic leukemia outcomes; however, toxicity and resistance limit its clinical use in other tumors. Here, we report that, in multiple myeloma (MM) cells, the DNA methylation status is significantly associated with reduced expression of ASNase-related gene signatures, thus suggesting ASNase sensitivity for this tumor. Therefore, we tested the effects of ASNase purified from Erwinia chrysanthemi (Erw-ASNase), combined with the next-generation proteasome inhibitor (PI) carfilzomib. We observed an impressive synergistic effect on MM cells, whereas normal peripheral blood mononuclear cells were not affected. Importantly, this effect was associated with increased reactive oxygen species (ROS) generation, compounded mitochondrial damage, and Nrf2 upregulation, regardless of the c-Myc oncogenic-specific program. Furthermore, the cotreatment resulted in genomic instability and DNA repair mechanism impairment via increased mitochondrial oxidative stress, which further enhanced its antitumor activity. Interestingly, carfilzomib-resistant cells were found to be highly dependent on amino acid starvation, as reflected by their higher sensitivity to Erw-ASNase treatment compared with isogenic cells. Overall, by affecting several cellular programs, Erw-ASNase makes MM cells more vulnerable to carfilzomib, providing proof of concept for clinical use of this combination as a novel strategy to enhance PI sensitivity in MM patients.
•Metabolic landscape of MM cells supports the relevance of amino acid depletion as a novel anti-MM therapeutic strategy.•Erw-ASNase combined with proteasome inhibition results in synergistic anti-MM effects by inducing ROS-mediated cell death.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32915979</pmid><doi>10.1182/bloodadvances.2020001639</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-6094-4351</orcidid><orcidid>https://orcid.org/0000-0001-9143-3714</orcidid><orcidid>https://orcid.org/0000-0003-3166-6078</orcidid><orcidid>https://orcid.org/0000-0001-7388-188X</orcidid><orcidid>https://orcid.org/0000-0002-2545-1401</orcidid><orcidid>https://orcid.org/0000-0002-1530-6729</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2473-9529 |
ispartof | Blood advances, 2020-09, Vol.4 (18), p.4312-4326 |
issn | 2473-9529 2473-9537 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7509874 |
source | PubMed (Medline); ScienceDirect (Online service) |
subjects | Amino Acids Asparaginase - pharmacology Cell Death Humans Leukocytes, Mononuclear Lymphoid Neoplasia Mitochondria Oligopeptides Reactive Oxygen Species |
title | Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T09%3A35%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amino%20acid%20depletion%20triggered%20by%20%CA%9F-asparaginase%20sensitizes%20MM%20cells%20to%20carfilzomib%20by%20inducing%20mitochondria%20ROS-mediated%20cell%20death&rft.jtitle=Blood%20advances&rft.au=Soncini,%20Debora&rft.date=2020-09-22&rft.volume=4&rft.issue=18&rft.spage=4312&rft.epage=4326&rft.pages=4312-4326&rft.issn=2473-9529&rft.eissn=2473-9537&rft_id=info:doi/10.1182/bloodadvances.2020001639&rft_dat=%3Cproquest_pubme%3E2442213993%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3949-61f80997409e2c1a4a8c109d40f037ad5a493d580d3a92f19b872375f3f7bc183%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2442213993&rft_id=info:pmid/32915979&rfr_iscdi=true |